Cangene Corp Terminates Acquisition of Hemophilia Compound IB1001 Amidst Inspiration's Bankruptcy Proceedings

By

Cangene Corp. has announced the closure of the acquisition of late stage hemophilia compound IB1001 developed by Ipsen and Inspiration Biopharmaceuticals Inc. for treating and preventing bleeding episodes in hemophilia B patients.

The development of IB1001 program comprises a surgery sub-study and information on safety, pharmacokinetic and efficacy from Phase 3 clinical trials in people with hemophilia B.

The U.S. FDA and the European Medicines Agency (EMA) have been conducting a regulatory review of IB1001.

The closure announcement came after the bankruptcy proceedings filed by Inspiration. Other assets that were also closed include recombinants IB1007 and IB1008 which are in pre-clinical development.

© 2024 VCPOST.com All rights reserved. Do not reproduce without permission.

Join the Conversation

Real Time Analytics